What are treatment options for prostate cancer

Treatment Options for Prostate Cancer

Prostate cancer treatment depends on several important factors, including the stage of your cancer (whether it's localized to the prostate or has spread), how aggressive it is, your age, overall health, and your personal preferences. Let me walk you through the main categories of treatment.

---

Early-Stage (Localized) Prostate Cancer

According to the NCCN Guidelines for Patients: Early-Stage Prostate Cancer, when cancer is confined to the prostate, you have several options:

Active Surveillance (Preferred for Lower-Risk Cancer)

This is the preferred strategy for most patients with lower-risk prostate cancer who have a longer life expectancy. Active surveillance means:

• Regular PSA blood tests
• Periodic biopsies (tissue samples)
• Digital rectal exams
• Close monitoring to catch any changes early

The goal is to avoid unnecessary treatment while watching carefully for signs that the cancer is becoming more aggressive.

Surgery (Radical Prostatectomy)

This procedure removes the entire prostate gland, surrounding tissue, seminal vesicles (fluid-producing glands), and sometimes nearby lymph nodes. The surgeon aims to remove all cancer while leaving a negative surgical margin (no cancer cells at the edges of removed tissue).

Radiation Therapy

Two main types are used:

• External Beam Radiation Therapy (EBRT): Targeted radiation from outside the body
• Brachytherapy: Radioactive seeds placed directly into the prostate

For higher-risk cancers, radiation is often combined with hormone therapy for 2-3 years to improve outcomes.

Hormone Therapy (for Higher-Risk Cases)

Also called Androgen Deprivation Therapy (ADT), this treatment reduces testosterone levels, which fuels prostate cancer growth. According to the NCCN guidelines, hormone therapy may be combined with radiation for high-risk or very-high-risk early-stage cancers.

---

Regional Prostate Cancer (Spread to Nearby Tissues)

When cancer has spread beyond the prostate but not to distant sites, the NCCN Guidelines recommend:

Preferred Approach:

• Radiation therapy (EBRT) + Long-term hormone therapy (2-3 years) + Abiraterone (a hormone-blocking drug)
• If you take abiraterone, you'll also receive a steroid medication to reduce side effects

Alternative Options:

• Radiation therapy + hormone therapy alone (without abiraterone)
• Hormone therapy alone (for patients with other serious health conditions)
• Surgery with lymph node removal (in selected cases)

---

Advanced/Metastatic Prostate Cancer (Spread to Distant Sites)

When prostate cancer has spread to bones, organs, or distant lymph nodes, systemic (whole-body) treatment is needed. According to the NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer, treatment depends on whether the cancer is still responding to hormone therapy.

Hormone-Sensitive Metastatic Prostate Cancer (Still Responding to Hormone Therapy)

Preferred treatments include:

• ADT + a second hormone-reducing medicine (abiraterone, apalutamide, or enzalutamide)

  • Research shows patients live longer on this combination than ADT alone
  • If taking abiraterone, a steroid is also given

• Triplet therapy (for high-volume cancer): ADT + chemotherapy (docetaxel) + a hormone-reducing medicine

  • This is only recommended for patients with extensive cancer spread who can physically tolerate the combination

Hormone-Resistant Metastatic Prostate Cancer (No Longer Responding to Hormone Therapy)

When cancer continues to grow despite low testosterone levels, options include:

Second Hormone Therapies:

• Abiraterone (Zytiga)
• Enzalutamide (Xtandi)
• Other anti-androgen medications

Chemotherapy:

• Docetaxel (Taxotere) - the most commonly used chemotherapy
• Cabazitaxel (Jevtana) - if docetaxel isn't effective
• Other options for very aggressive cancers

Immunotherapy:

• Sipuleucel-T (Provenge) - for patients with few symptoms
• Pembrolizumab (Keytruda) - for patients with specific genetic markers (mismatch repair deficiency)

Targeted Therapies:

• PARP inhibitors (olaparib, talazoparib) - if you have BRCA1 or BRCA2 gene mutations
• Radiopharmaceuticals like lutetium-177 (Pluvicto) - radioactive particles that attach to cancer cells

---

Key Questions to Ask Your Oncology Team

1. What stage is my prostate cancer, and what does that mean for my treatment options?

2. Based on my specific test results and overall health, which treatment approach do you recommend and why?

3. What are the potential side effects of each treatment option, and how might they affect my quality of life?

4. If my first treatment doesn't work as expected, what are my next options?

5. Are there clinical trials available that might be appropriate for my situation?

6. How often will I need follow-up appointments and monitoring after treatment?

7. What supportive care services are available to help manage side effects?

---

Important Reminders

The NCCN Guidelines emphasize that prostate cancer is complex with many treatment options. Many patients with advanced prostate cancer eventually receive two, three, or more different therapies over time as their cancer evolves. Your care team will personalize your treatment plan based on your complete clinical picture—not just one test result or factor.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.